Cigna Corporation (NYSE:CI)
Cigna Corporation (NYSE:CI), ended its previous trading session at $225.22 showing a gain of 5.30000000000001 or 2.41 percent with respect to the price of $219.92 when stock market opened. The company traded 2.12 Million shares over the course of the trading day. Giving the average volume of 2.01 Million over the course of 3 consecutive months. Which signifies a pretty good change over the time with its shares outstanding of 364.43 Million.
Cigna Corporation (NYSE:CI) is currently trading lower than its price target which is set to $255.68 by the analyst. The stock is 0.12% Above its 1-Year High which is $224.96. CI has a difference of 90.06% from its 1 year low which stands at $118.50. The company is currently rated by analyst who are keeping a close eye on the stock as 1.9. Where 1 means Buy, 2.5 meaning Hold and 5 as Sell.
Cigna Corporation (NYSE:CI) Performance Snapshot
The stock performed exceptionally good in the previous week which depicts an increase of 10.71 percent in the shares price. The company added about 5.91% in its share price over 1-Month. While taking about the performance of the stock over 1-year interval is 10.67 Percent. CI currently shows 8.19% as its year to date performance.
Cigna Corporation (NYSE:CI) Price Insight
The stock needs to grow about $30.46 to reach its price target. In order to seek the stock’s directional movements, 20-Days, 50 Days and 200-Days moving averages are 9.64%, 8.98% and 19.91 percent respectively. The stock trades about 1.02 percent of its Float giving its total shares Outstanding are 364.43 Million. CI gained about 23.63 percent in 6 months showing its Average True Range of 6.41. The company currently has a RSI and Beta of 68.95 and 0.85.
While talking about Cigna Corporation (NYSE:CI) valuation ratios, the stock trades with a P/S and P/B of 0.52 and 1.71 which is significantly better and attractive as compared to its peers.
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)
Performance Indicators of Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) Analytical Review